The Trump administration awarded a small biosecurity company nearly $40 million to screen for Ebola and other infectious diseases just months after a firm linked to President Donald Trump's elder sons invested in its parent company, according to records and interviews. The contracts, one to screen for Ebola in several U.S. airports and the other to respond to disease outbreaks in the Democratic Republic of Congo, are seven times the total value of government contracts the company had directly received before. The company, XpresTest, has years of experience monitoring for COVID-19 and other diseases for the government at U.S. airports. That makes its parent, XWELL, an unusual hybrid, selling both spa treatments and biosecurity services. Last year, it made most of its money from waxing salons and airport spas that offer manicures, massages and "chakra beds."